ADELA
PHASE III TRIAL RANDOMIZED TRIAL OF ELACESTRANT PLUS EVEROLIMUS VERSUS ELACESTRANT IN PATIENTS WITH ER+/HER2- ESR-MUTATED ADVANCED BREAST CANCER REFRACTORY TO CDK4/6 INHIBITORS PLUS ENDOCRINE THERAPY
A RANDOMIZED PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ELACESTRANT PLUS EVEROLIMUS VERSUS ELACESTRANT IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE, ESR1-MUTATED, ADVANCED BREAST CANCER PROGRESSING TO ENDOCRINE THERAPY AND CDK4/6 INHIBITORS.
COUNTRY
STATUS
TUMOR TYPE
PHASE
N
SITES
ER+/HER2- ABC
110
240
III
Austria, Brazil, Czech Republic, Spain, France, Greece, Italy, Germany, UK
Recruiting
CLINICAL TRIAL DETAILS
PRESS RELEASE
SCIENTIFIC IMPACT
ASCO 2026 poster: https://www.medsir.org/_files/ugd/39f166_769ed0cd63874a80ba33676c57f03085.pdf | ASCO 2025 poster: https://www.medsir.org/_files/ugd/39f166_11a5f2c8619c413baac7192e87bf1243.pdf | ASCO 2025 lay language summary: https://www.medsir.org/_files/ugd/39f166_0db8f64c0db346d085c216e5af9ab143.pdf | MBCC 2025 poster: https://www.medsir.org/_files/ugd/39f166_6c5baaf203cf43a8a06e54334daf0a5a.pdf | SABCS 2024 poster: https://www.medsir.org/_files/ugd/39f166_d4d599c793074f84a87caa0c7146716e.pdf | SABCS 2024 lay language summary: https://www.medsir.org/_files/ugd/39f166_7fac9ff741d246a7897e8892843c9f45.pdf
BLOG ARTICLES RELATED
TRIAL SITES